19.06.2018 • NewsChinaDede WillamsHIV drug

China Develops new HIV Drug

China Develops new HIV Drug (c) Frontier
China Develops new HIV Drug (c) Frontier

Albuvirtide, a new drug developed by Frontier Biotechnologies in China, is claimed to be the world's first long-acting fusion inhibitor for HIV. It works by blocking the fusion between the virus and the host cell membranes, interrupting the virus's life cycle before it has begun to do harm.

What makes this treatment more attractive to patients, Chinese reports said, is that unlike many other drugs on the market it has to be injected only once a week. According to the Xinhua news agency, Albuvirtide also has been shown to have fewer side effects, particularly on the liver, compared to current treatments in China.

All HIV treatments available in the People’s Republic are imported or generic, and patients typically take a daily cocktail of pills. Xie Dong, chief scientist and former head of Frontier Biotechnologies, told Xinhua that China's first domestically developed HIV drug offers patients a new treatment option. “We hope to dispel the fact that China has not developed good anti-AIDS medicine,” he added.

While the new drug is expected to improve patient compliance, reduce costs and improve patient quality of life, Pend Xiaohui, a sexologist at Central China Normal University, told the newspaper Global Times that patients will have to overcome the psychological obstacle of injecting the medicine on their own, or have a doctor do it for them.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.